This report was first published by Endpoints News. To see the original version, click here
Sarepta CEO Doug Ingram is stepping down from his role by the end of the year, ending a brash tenure in which he brought several Duchenne muscular dystrophy products to market and later presided over a spiraling share price amid intense safety and regulatory questions.
Ingram said he was retiring for family reasons, calling the decision “deeply difficult.” He said he’d been traveling between the company’s Massachusetts headquarters and his family in California, and that two of his immediate family members were diagnosed with myotonic dystrophy type 1, a progressive genetic muscle disease.
您已阅读22%（684字），剩余78%（2379字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。